Nalbuphine extended release - Trevi Therapeutics
Alternative Names: Haduvio; Nalbuphine ER; Nalbuphine extended-release; PW-4142; T 111Latest Information Update: 14 Aug 2024
At a glance
- Originator Penwest Pharmaceuticals
- Developer Endo Pharmaceuticals; MentiNova; Rutgers; Trevi Therapeutics
- Class Analgesics; Antipruritics; Antitussives; Morphinans; Opioid analgesics; Skin disorder therapies; Small molecules
- Mechanism of Action Opioid kappa receptor agonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Prurigo nodularis; Pruritus
- Phase II Cough
- No development reported Drug-induced dyskinesia
- Discontinued Pain
Most Recent Events
- 08 Aug 2024 MHRA approves IND application for phase Ib TIDAL respiratory physiology trial of Nalbuphine extended release in Idiopathic pulmonary fibrosis
- 07 May 2024 Trevi Therapeutics plans a phase Ib TIDAL respiratory physiology trial for Idiopathic pulmonary fibrosis patients in USA and UK in third quarter of 2024
- 07 May 2024 US FDA approves IND application for phase Ib respiratory physiology trial of Nalbuphine extended release in Idiopathic pulmonary fibrosis